Article
How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals
Nuclear Medicine Communications
(2012)
Disciplines
Publication Date
July 1, 2012
DOI
10.1097/MNM.0B013E3283529BF7
Citation Information
Ka Kit Wong, Amanda M. Laird, Amir Moubayed, Sotirios Chondrogiannis, et al.. "How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals" Nuclear Medicine Communications Vol. 33 Iss. 7 (2012) p. 679 - 688 Available at: http://works.bepress.com/amir-moubayed/1/